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Malaria is still an epidemic in many parts of the world—about 220 million people are still 
infected with malaria worldwide and about 700 thousand people die from this disease per 
year.  Most of the drugs used to treat malaria work well if they are used as required and 
they contain the right amounts of the active ingredient; however, it is estimated that more 
than 10% of drugs traded worldwide are counterfeits including 38% to 53% of 
antimalarial tablets produced in China and India.  Due to the lack of data covering the 
extent of counterfeit antimalarial drugs in Ghana, the purpose of this quantitative study 
was to determine the percentage of counterfeit antimalarial drugs sold in Ghana by 
assessing the amounts of the 2 most common antimalarial drugs, artemether (ATMT) and 
lumefantrine (LMFT) sold in Ghana retail outlets. These drugs were purchased from 
retail outlets in Ghana and analyses at the Mayo Clinic Pharmacology core lab 
(Rochester, MN). The quality of the drugs were characterized by comparing the actual 
amount of ATMT & LMFT in each tablet to the expected amount. Using explanatory 
theory along with dose response-response occupancy theory, the researcher addressed 
quantitative solutions to questions related to the percentage and distribution of counterfeit 
ATMT and LMFT tablets.  The results revealed that overall 20% of the drugs are 
counterfeit; this is not dependent on the location or kind of outlet but rather depends on 
whether the tablets were imported or locally manufactured and whether the tablets had a 
pedigree scratch panel. This study provides a better understanding of how much 
antimalarial medication is counterfeit in Ghana, which will aid interventions to minimize 
the adverse effects of counterfeit antimalarial medication in Ghana. 
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Chapter 1: Introduction to the Study 
About 220 million people are infected with malaria worldwide and thousands of 
people die from it yearly (Nadjm & Behrens, 2012; World Health Organization [WHO], 
2013).  The prevalence and mortality rate in sub-Saharan countries related to malaria is 
very high, and the rate of deaths for children from these countries is worse.  Malaria is 
caused by parasites called plasmodium sp. (Zhou et al., 2014), which use mosquitos as 
vectors for transmission to humans.  Malaria eradication and treatment has been based on 
the different stages of the life cycle of the plasmodium parasite.  Malaria can be treated 
with several drugs, and a majority of these drugs work well if used appropriately and they 
contain the right amounts of the active ingredient.  It is believed that a high percentage of 
these drugs may be counterfeit in Ghana, especially those imported from Southeast Asia 
(Amin, Snow, & Kokwaro, 2006).  At this time, little is known about how much of these 
medications are fake.  I addressed the counterfeit problem by empirically finding out how 
much antimalarial medication is counterfeit. 
Background of the Study 
Malaria has been in existence and has been well known for over 2,000 years, but a 
majority of discoveries regarding malaria happened in late 19th century. Several Nobel 
Laureates made discoveries, including Laveran, who discovered the parasite in 1880, and 
Ross, who discovered that malaria is transmitted by mosquitos in 1897 (Rajakumar & 
Weisse, 1999).  At the turn of the 20th century, several public health departments 
including the United States Public Health Service (USPHS) began trying to find ways to 




This resulted in the discovery of Chloroquine as an effective drug for treating malaria, 
while Dichloro-diphenyl-trichloroethane (DDT), an insecticide, was used to control and 
eradicate malaria in the US and most western countries (Roberts, Laughlin, Hsheih, & 
Legters, 1997).  Eradication efforts were very successful in many countries due to the 
efforts of the CDC, which started as the Communicable Disease Center as a part of 
malarial control and eradication centers in the US (CDC, 2009); however, sub-Saharan 
countries were not part of efforts for malaria eradication.  Malaria is still an epidemic in 
sub-Saharan countries and a majority of the region’s population die yearly from this 
disease (Nadjm & Behrens, 2012; WHO, 2013).  About one-third of 100 countries 
worldwide suffer from a high mortality rate due to malaria, and more than 95% of these 
countries are in sub-Saharan Africa.  Ghana, like most of developing sub-Saharan 
countries, is still struggling with challenges with basic health care.  The lack of effective 
health care makes the system very vulnerable and easy for counterfeit medication to 
infiltrate the market; over 100,000 deaths per year in Africa are due to counterfeit 
medication (WHO, 2014).  In recent years, there has been some coverage about 
counterfeit antimalarial drugs in Ghana because it directly affected s politician (Daily 
Guide, 2013). It is believed that majority of the counterfeit medication comes from South 
East Asia (Bate & Hess, 2010), but the extent of counterfeit medication in Ghana is not 
known except as described in a few publications and pilot studies (Asuamah, Owusu-
Prempeh, & Antwi-Boateng, 2013; Bate & Hess, 2010). This study will make up for this 





Statement of the Problem 
Most information on the percentage of counterfeit drugs in the sub-Saharan 
African region is speculative or based on anecdotal evidence; there has not been an 
extensive study on the whole country that has empirically determined the percentage of 
counterfeit antimalarial medication in the Ghana (Asuamah et al., 2013).  This study will 
fill this gap in literature to address potential for intervention.  The two most commonly 
used antimalarial medication in this region are artemether (ATMT) and lumefantrine 
(LMFT) (Lozano et al., 2012).  This study empirically determined the percent of 
antimalarial medication using ATMT and LMFT that is counterfeit in pharmaceutical 
retail outlets in Ghana.  
Purpose of the Study 
The purpose of this quantitative study was to explore the extent of antimalarial 
counterfeiting by looking at the percentage of ATMT and LMFT in drugs sold in retail 
outlets in Ghana that is counterfeit.  Fake drugs pose three direct threats to patients: 
failure to provide effective treatments, which is estimated to cause thousands of deaths 
per year; adulteration with toxic chemicals that leads to fatalities; and substandard drugs 
that expose the parasites to sublethal doses, which can cause them to develop a resistance 
to the medications (Attaran et al., 2012).  To reverse the trend of fake and substandard 
drugs, we need an understanding of the extent of counterfeit medication in Ghana. With 
this understanding, we can develop proper interventions to potentially minimize the 
adverse effects of counterfeit antimalarial medication in Ghana.  One covariate I assessed 




the differences between pharmacies and licensed chemical stores and geographical 
implications on the percent of counterfeit medication in Ghana. 
Filling Gaps in the Literature 
Professional Applications 
This study provides the information and data needed to understand the 
geographical spread of the counterfeit problem in Ghana, which is relevant for 
intervention. Adequate mechanisms for treating malaria ailments must be in place to have 
proper interventions to prevent and fight this disease. Since this study was performed at 
different geographical regions in Ghana, it gave us the opportunity to look at the trend of 
counterfeit medication within different regions of the country. It can also help us to 
measure the impact of an intervention. 
Social Change Implications 
The implications for positive social change include a better understanding of how 
much the anti-malaria medication is counterfeit and the extent of counterfeit medication 
in Ghana, which is needed for interventions that will potentially help minimize the 
adverse effects of counterfeit antimalarial medication in Ghana. 
Framework 
For this study, I combined explanatory theory, which is a public health theory, 
with the dose response-receptor occupancy theory in pharmacology.  Glanz and National 
Cancer Institute (2005) write that explanatory theory illustrates the nature of the problem 
such as the factors that cause the problem and the changes required to rectify the issues 




treatment and other related factors affecting the treatment.  One of the factors affecting 
malaria treatment is the distribution of counterfeit drugs, which works with the dose 
response-receptor occupancy theory used in pharmacology, as it was even used to explain 
the effect of the amount of dose in a malaria drug, the efficacy of the drug, or toxicity of 
the drug (Rang, 2006).  Researchers use this theory to examine how the effect or response 
to a drug is directly proportional to the number of receptors occupied by that drug.  A 
drug will only produce a maximum effect if all the receptors needed to elicit the effect or 
responses are occupied (Brunton et al., 2011).  This means that for antimalarial 
medications, the total efficacy can only be achieved if all the receptors needed to destroy 
the plasmodium parasite are occupied.  A counterfeit drug is defined by WHO (2013) as a 
drug whose identity and source has been deliberately mislabeled.  Counterfeit products 
have a wide spectrum; this includes those with wrong active ingredients, expired drugs, 
and those with subtherapeutic amounts of the active ingredient.  For a counterfeit drug, 
whether substandard or fake, either the receptors are not fully occupied, or they are not 
occupied at all. This means that substandard and fake drugs will not produce the required 
effect, thereby affecting the treatment and the malaria epidemic. 
The burden of malaria is still high in Ghana, with almost 350 cases reported per 
1,000 of cases of malaria among young children below the age of 5 years (Asante et al., 
2011). The prompt treatment or management of malaria is necessary for the control and 
elimination of the disease (Band et al., 2013).  Effective treatment can also reduce drug 
resistance since it reduces the frequency of mutation of the parasite. Ineffective treatment 




makes the disease difficult to treat as it renders current medications ineffective (Tordrup, 
Virenfeldt, Andersen, & Petersen, 2011).  The WHO highly recommends artemisinin-
based combination therapies (ACTs); two of the most commonly used are generic ATMT 
and LMFT (Lozano et al., 2012). Unfortunately, according to the CDC (2013), it is 
estimated that 10% to 30% of all medicines sold in the developing world are counterfeit.  
A report from the Institute of Medicine (2013) says that counterfeit drugs were sold in 
more than 124 countries in 2011 alone.  Most of these counterfeit medications are in sub-
Saharan Africa ranging from about 12% to 50%. Some studies in parts of Africa has 
shown that about 45% of sulphadoxine-pyrimethamine (SP) and 33.0% of LMFT were 
counterfeit (Amin, Snow, & Kokwaro, 2005).  Most of these counterfeit drugs are 
shipped from Asia (Newton et al., 2011) and are a result of the lack of effective health 
care and regulations.  Few studies have been conducted on the quality of the medication 
in Ghana, and researchers have worked with limited samples and insufficient theories. 
The results of a small pilot study in 2013 on the quality of artemether and lumefantrine 
found that 17% of the drugs they tested had quality issues (Affum et al., 2013).  Bate et 
al. (2008) found that about 35% of the drugs were counterfeit in Ghana and other African 
countries; however, they did not look at the efficacy of the drugs (Bate et al., 2008).  
Others saw the percentage of counterfeit drugs in Ghana ranging from 54% to 94% 
depending on the method used to check the quality of the drug. Using a receptor theory is 
more effective in examining counterfeit malaria drugs, because researchers can see the 





While it may not be possible at this time to ensure all drugs in Ghana are not 
counterfeit, it is a goal to strive for. For now, researchers can investigate if a minimum 
percentage of the drug in the country is counterfeit and as a result assess a low threshold 
for counterfeit product.  
RQ1: Is there a difference between the percentage of counterfeit medication in 
pharmacies found in the cities and those found in the rural areas? 
Ho1: There is no difference between the percentages of counterfeit medication in 
pharmacies found in the cities versus those found in the rural areas. 
Ha1: There is a difference between the percentages of counterfeit medication in 
pharmacies found in the cities versus those found in the rural areas. 
RQ2: Is there a difference in the percentage of counterfeit drugs between 
pharmacies and licensed chemical sellers? 
Ho2: There is no difference in the percentage of counterfeit drugs between 
pharmacies and licensed chemical sellers. 
Ha2: There is a difference in the percentage of counterfeit drugs between 
pharmacies and licensed chemical sellers. 
RQ3: Is there a difference in the percentage of counterfeit drugs between 
imported artemether and lumefantrine and locally manufactured ones? 
Ho3: There is no difference in the percentage of counterfeit drugs between 
imported Artemether and Lumefantrine versus locally manufactured ones. 




artemether and lumefantrine that is imported versus locally manufactured ones. 
 RQ4: Is there a difference in the percentage of counterfeit drugs between government 
hospitals and those from nongovernmental hospitals? 
Ho4: There is no difference in the percentage of counterfeit between government 
hospitals and those from nongovernment sources. 
Ha4: There is a difference in the percentage of counterfeit drugs between 
government hospitals and those from nongovernment sources. 
Nature of the Study 
This study was a cross sectional correlational study and the samples was chosen 
using a statistically suggested sample size to ensure that there is enough power for the 
population to reduce any biases.  The quantitative method was used because it is the best 
way to assess a situation or a problem analytically (Fowler, 2009).  This study required 
systematic measurement of study samples in the lab using validated analytical techniques.  
The study variables were the concentration of artemether and lumefantrine (dependent) 
which is measured in milligram per milliliter of solution.  The independent variables were 
the pharmacies and licensed chemical sellers (LCS) where the samples were acquired, 
which included different locations for private and government owned pharmacies, 
wholesale stores, and licensed chemical sellers.  I acquired the samples from the retailers 
and sent them to the lab to determine the concentration of artemether and lumefantrine 
using High Pressure Liquid Chromatography (HPLC).  The covariate of the study was the 





Definition of Terms  
 Antimalarial medication: Drugs used to prevent or cure malaria.  This includes 
the treatment individuals with both confirmed and suspected infection.  These drugs may 
sometimes be used for prevention.  
Concentration of drug: The amount of drug per volume of solution.  This can 
either be milligrams per milliliters or grams of drug per liter of water. 
Quality of drug/medication: In this project, the term quality is based strictly on the 
amount of drug as compared to the expected amount as written on the label.  This was 
measured in percentage of the drug that is fake or counterfeit.  
Counterfeit/fake drug: For this study counterfeit drugs shall refer to drugs without 
the active ingredients and subtherapeutic amounts of active ingredient.  
Subtherapeutic drug: Has the correct ingredient, but the amount of drug is less 
than the labeled amount. 
Active ingredients: The substance/s in the drug that are supposed to provide the 
therapeutic effect.  In this study, the active ingredients are artemether and lumefantrine.  
Dose: The quantity of drugs taken or prescribed. 
Drug efficacy: A drug’s capacity to produce a desired effect or endpoint.  For an 
antimalarial drug, the efficacy is its capacity to kill malaria parasites. 
High Pressure Liquid Chromatography (HPLC): An analytical technique used 
mostly in chemistry used to separate mixture of substances in liquid at high pressures.  




Pharmacies: Stores with registered pharmacists preparing, dispensing, and selling 
drugs. 
Licensed chemical sellers (LCS): Stores mostly run by pharmacy technicians 
approved by the government of Ghana selling and dispensing some drugs without the 
supervision of a pharmacist. 
Private Pharmacies: Pharmacies run and owned by the private sector and not 
government. 
Government pharmacies: Pharmacies run and owned by the government. 
Wholesale: Outlets distributing drugs to the retail outlets including pharmacies 
and LCS. 
Cities: Urban communities that have utilities, public transportation, modern 
sanitation, large population density, and businesses.  
Small towns and villages: Communities lacking some or all utilities like pipe-born 
water, public transportation, modern sanitation, and businesses. 
Assumptions  
This quantitative study investigated the extent of counterfeit drug using the two 
most prescribed antimalarial medication (artemether and lumefantrine) in Ghana. This 
research included the following assumptions in the study: 
1. The data collected from each pharmacy or LCS in a population represents 
the information for the whole population.  This assumption was necessary 




2. That ATMT and LMFT purchased from a store represent the quality of 
all ATMT and LMFT from that store.  This assumption allowed the use a 
few drugs to represent all the drugs in a particular store 
3. Data from ATMT and LMFT was a good representation most popular 
anti-malarial medication in Ghana.  
4. The drugs are only acquired via the above mentioned outlets.  This means 
that the number of all other possible outlets is so small that their 
contribution to this data with be insignificant.  This validated the fact that 
the samples used for this study represented all the drugs in the 
population. 
Scope and Delimitations 
Artemether-lumefantrine combination tablets from public and private (local retail 
pharmacies) in Ghana can be obtained in two formalized ways: traditional pharmacies 
with a trained pharmacist and LCS.  LCS sell drugs mostly in suburbs, small towns, and 
villages, without any supervision of a pharmacist, but they are licensed by the 
government to sell over-the-counter medication and common medications authorized by 
the government.  Because these are not well controlled or monitored, the LCS sells 
almost the same medications sold by the pharmacies.  
Geographically, Ghana is divided into ten regions; the capital of Ghana is Accra 
and the second largest city is Kumasi.  Most of the pharmacies are in the major cities 
within the ten regions.  The Greater Accra Region has two main sub cities within it: the 




main city for the Ashanti Region.  According to the Ghana Pharmacy Council, there are 
429 Pharmacies and 9,210 licensed chemical sellers throughout the country.  Most of the 
pharmacies are in the four major cities. The city of Accra has about half (233), Kumasi 
has (79) pharmacies, and the other two major cities have 40, and the rest are spread 
throughout the country mostly in the bigger towns.  The LCS are more spread out as they 
serve more remote and rural communities.  I assessed these areas, with inclusion criteria 
involving all registered pharmacies (private and government) and all licensed chemical 
shops in the selected towns; exclusion criteria included unregistered stores that sells 
drugs or any person selling drugs on the streets illegally. 
A generalization for this study was the assumption that a few drugs from one store 
represent the quality (counterfeit or not) of all drugs in that store.  Another generalization 
was assuming a few randomly picked stores represent the entire pharmaceutical retail 
outlets in the country.  
Limitations 
The choice to study Ghana presents a bias because of my connection to that 
country (place of birth), which may have excluded other sub-Saharan African countries 
that would present different data.  Another limitation of this study was that the study may 
not capture all possible outlets, which includes possible illegal outlets that may exist in 
the system.  If these numbers are significant, this will affect the internal validity of the 
study since the outcome of the study may not be a true representation on the population.  
Other confounding variables like price of the drug and lack prescription that is acceptable 




making sure the data collection process is done correctly, based on statistics and sampling 
is random. 
Significance of the Study  
Malaria is still endemic in sub-Saharan countries like Ghana.  It is treatable and 
there are several medications in the market; however, some studies have shown that many 
of these drugs are counterfeit, with a small pilot study revealing that 30% to 40% of 
antimalarial medication counterfeit.  If this is true, then any eradication program will 
have to include reducing or eliminating counterfeit medication in these countries.  Since 
there is no data quantifying the percentage of antimalarial drugs that are counterfeit this 
study was to solve that problem. This study will give information needed to decide if the 
reduction or eradication of counterfeit medication in Ghana and other sub-Saharan 
countries should be part of malaria eradications strategies. Since this study was 
performed at different geographical regions in Ghana, it will also provide the opportunity 
to look at the trend of counterfeit medication within different regions of the country, 
which will increase efficiency in intervention and measuring of the impact of such 
intervention. 
Summary 
Over 200 million people worldwide are infected with malaria and more than half 
a million people are dying from it per year.  Malaria is a treatable disease with several 
medications in the market, but several pilot studies have revealed the possibility of 
counterfeit antimalarial medication as one of the factors affecting the treatment of 




extent of counterfeit antimalarial medication in the system (Asuamah, Owusu-Prempeh, 
& Antwi-Boateng, 2013).  Using Ghana as an example and two of the most common 
antimalarial drugs in Ghana—ATMT and LMFT—this study explored the extent of 
antimalarial counterfeiting, if any, from pharmaceutical retail outlets in Ghana.  This 
study aimed to address the lack of data on the extent of counterfeit antimalarial drugs in 
Ghana and sub-Saharan Africa in general.  Chapter 2 will include an overall review of the 




Chapter 2: Literature Review 
Introduction 
Even though there have been speculations about the extent of the counterfeit 
problem in some of the countries that suffer from malaria epidemics, there has not been 
an extensive study on the whole country (Ghana) that has empirically determined the 
extent of counterfeit antimalarial medication in the system (Asuamah, Owusu-Prempeh, 
& Antwi-Boateng, 2013), and there is little to no empirical evidence of the percentage of 
drugs in the sub-Saharan region that are counterfeit.  Due to this gap in the literature on 
counterfeit medication, I empirically determined the percent of antimalarial medication 
that is counterfeit in pharmaceutical retail outlets in Ghana. 
In this chapter, I will discuss the strategies used to conduct the literature review as 
well as the epidemiology, which will include the incidence and prevalence and the mode 
of infection of malaria.  There will also so be emphasis on past research about malaria, 
the problems with counterfeit drugs, and how counterfeit medication affects the malaria.  
This chapter will also provide analysis on how drugs are distributed in Ghana, the 
sources, and where they are manufactured.  In addition, I will discuss the explanatory 
theory which is a public health theory combined with the receptor occupancy theory in 
pharmacology and how these two theories were applied to the characterization of the 





Literature Search Strategy 
Several types and sources of information or data revealing research studies were 
used for this literature review.  The research included a review of other peer reviewed 
manuscripts and studies on malaria and counterfeit drugs.  Most of the research was from 
primary articles, which means I excluded review articles and reports or studies without 
original research.  Literature search was done using keywords like malaria, counterfeit 
drugs, counterfeit medication, and antimalarial medication, malaria treatment, malaria 
in Ghana, and receptor occupancy and explanatory theory in different combinations.  
Most of the search criteria was based on literature published from 2008–2014.  The 
following databases were used: PUBMED, Library of Congress, EMBASE, MEDLINE, 
ScienceDirect, Pre-CINAHL, CINAHL, ProQuest and Dissertations & Theses, Web of 
Science, and the Walden University database of dissertations.  Other search engines 
included Google Scholar, and I examined the WHO and the Centers for Disease Control 
and Prevention (CDC) websites for relevant information.  
Using malaria as a keyword alone gave me 69,103 articles.  This was obviously 
difficult to use and unfocused, so I combined some of the keywords for better results.  
For instance, search results of malaria and Ghana and drugs showed 149 citations; out of 
these articles, eight articles were found to be acceptable.  Explanatory theory came up 
with 27 citations searched as a title, and six citations were acceptable. Ghana and fake 
medicine provided five citations, and four were used.  The total number of articles used 





For this study, I combined two theoretical concepts from two disciplines: 
explanatory theory, which is a public health theory, with the receptor occupancy theory in 
pharmacology.  
Explanatory Theory 
There is a great amount of evidence that suggested public health intervention and 
promotions based on theories are more effective than those without theories (Glanz & 
National Cancer Institute [NCI], 2005).  Explanatory theory, also known as the theory of 
the problem, was first used by Shapiro in psychiatry.  The theory is used to illustrate the 
nature of a problem by examining the factors that cause the problem that can be changed 
(Shapiro, 1953).  Researchers have used it in several ways to empirically determine or 
test several public health issues (Song et al., 2010), such as testing for postpartum fatigue 
in Korea, explaining metabolic depression in hibernation and major depression (Tsiouris, 
2005), and it was recently used to build another social epidemiology theory for 
depression in mothers (Eastwood, Jalaludin, & Kemp, 2014).  It has also been used in 
other disciplines such as economics with asset evaluation and human capital and in 
education for studies in learning curves and team learning (Vlismas & Venieris, 2009; 
Westwood, 1997).  The theory helps define the elements that influence particular 
behaviors, trends, or situations before moving on to find cause and solutions to the 
problem.  There are several concepts considered in this theory in relation to an ecological 
perspective; this includes intrapersonal, interpersonal, institutional, community factors 




Intrapersonal factors look at individual characteristics that affect behavior; examples are 
beliefs, attitudes and personality traits. Interpersonal looks at interpersonal processes and 
groups that provide support like families and friends. Institutional factors mostly involve 
rules and regulations and informal structures that could help or make a problem worse 
(McLeroy et al., 1988).  One of the goals of this study was to provide an improved 
approach in order to enhance the empirical understanding of the problem before 
developing intervention programs for counterfeit antimalarial medication and the malaria 
epidemic in general.  In this case, the problem is the malaria epidemic and its treatment, 
and among the many factors affecting the treatment is counterfeit antimalarial medication 
and its distribution.  In addition, receptor occupancy theory, which relates more to drugs 
and pharmacology, will address the amount of active drugs required for malaria 
intervention.  
Receptor Occupancy Theory 
Receptor occupancy theory is used in pharmacology to explain the effect of the  
dose of a drug and the efficacy or toxicity of the drug (Rang, 2006).  The receptor 
occupancy theory was first postulated by Langley in 1901 after his work on nicotine and 
curare, even though this idea of receptors controlling the effect of a drug was furthered by 
Ehrlich around the same period.  Langley’s model explains how a drugs activity affects 
receptors and then quantifies the drug concentration and effect elucidated by the drug, 
which links drug action to the number of receptors occupied by that drug (Christopoulos 
& El-Fakahany, 1999).  Drug effects on biological systems are quantified by assigning 




the biological system, since it is essential for the study of drugs mostly done in test 
systems.  This current study helps to isolate the effect of the drug in different systems and 
under different conditions.  A very important part of the theory is the assertion that the 
amount of drug bound to the cell is directly proportional to the response. Figure 1 
describes the proportionality equation between the amount of drug bound to the receptors 
and the response.    
 
Figure 1. Relation between drug bound and physiological effect.  
E is some physiological effect that happens as a result of the drug. An example is killing 
of plasmodium parasite. Emax is the maximum amount of this effect, DR is the amount of 
drug bound to the receptor and RT is the total amount of receptors. Retrieved from 
http://www.uky.edu/~mtp/pha522drug/OBI836mp06.html 
 
Figure 1 shows that the maximum effect is only realized if all the receptors are 
occupied by the drug.  Addressing the relationship between effect and receptor 
occupancy is shown in Figure 2.  In Figure 2, no matter what the relationship, the 






Figure 2. Relationship between effect and percent receptor occupancy. Source: Brunton 
et al, 2011. 
Receptor occupancy theory provides the basic framework of drug interactions and 
the way the drug behaves on the body, which is known as pharmacodynamics.  The 
theory states that the effect/response of a drug is directly proportional to the number of 
receptors occupied by that drug.  It also states that this drug will only produce a 
maximum effect if all the receptors needed to elicit the effect or responses are occupied.  
The approach could be applied to antimalarial medication, because for antimalarial 
medications, the total efficacy can only be achieved if all the receptors needed to destroy 
the plasmodium parasite are occupied.  Counterfeit drugs have a wide spectrum, which 
includes those with wrong active ingredients, those that have expired and relabeled, and 
those with subtherapeutic amounts of the active ingredient.  For a counterfeit drug, 
whether substandard or fake, either the receptors are not fully occupied, or they are not 
occupied at all. This means that substandard drugs will not produce the required effect 
since they will not occupy all the receptors, or the fake drug will not occupy the receptors 




Combination of Explanatory and the Receptor Occupancy Theory 
A combination of the two theories starts with the explanatory theory to ask 
questions and examine the problem (Figure 3).  The problem is the distribution of 
counterfeit antimalarial medication.  This theory will ask what the problem is, accessing 
the extent of the problem.  The next step of the process is the evaluation stage, which 
identifies when the receptor occupancy theory comes to play.  The evaluation stage will 
also look at the concentration on the drugs since this is related to the amount of drug 
needed to occupy the receptor.   
 
Figure 3. Theoretical framework. 
Transmission and Life Cycle of the Parasite 
The plasmodium sp. is the parasite that causes malaria (Zhou et al., 2014). The 
parasite uses two hosts—the mosquito (intermediate host) and the human (primary 
host)—in its life cycle as shown in Figure 4 (CDC, 2012).  There are three sub cycles: the 
exo-erythrocytic cycle (liver) and the erythrocytic (blood) cycle in the human host and 
the sporogonic cycle in the Anopheles mosquito (Florens et al., 2002).  An infected 
female Anopheles mosquito transmits the parasite (sporozoites) to the human host during 
feeding through the saliva, which it uses to prevent the coagulation of the blood; this is 




into the human liver cells where they become schizonts (Mahajan et al., 2008).  This 
stage can be dormant for even years in some species until they rupture to release 
merozoites (Riley et al., 2000).  Merozoites then infect red blood cells, initiating the 
erythrocytic cycle (Vaughan, Aly, & Kappe, 2008).  Merozoites mature into a ring stage 
called trophozoites which are responsible for the clinical manifestations of the disease 
and also produces the gametocytes which can be ingested by the Anopheles mosquito 
after which they enter into the sporogonic cycle (Aguilar et al., 2014). The zygotes are 
formed in the stomach of the mosquito, which becomes ookinetes; these are mobile and 
elongated which allows them to invade the wall of the mosquito’s stomach where they 
develop into oocysts.  These then rupture to release sporozoites, which move into the 
salivary glands of the mosquito.  Sporozoites can then be transmitted into the human host 
(Arakawa et al., 2005).  As we shall see later, the medication used for the treatment of 
malaria disrupts the different parts of the life cycle of the plasmodium parasite. 
It is important to know that there are several species of the plasmodium parasite 
(P. falciparum, P. vivax, P. malariae, and P. ovale), which adds to the variability of the 
signs, symptoms, and treatment of malaria (Kiwuwa et al., 2013).  Breeding of Anopheles 
mosquitos takes place in water, mostly in stagnant water (Tchouassi et al., 2012).  The 
longer the life spans of the mosquito, the more severe the epidemic, which is present 






Figure 4. Life Cycle of the plasmodium parasite. Adapted from CDC (2012). 
Signs and Symptoms 
Malaria symptoms are flu-like on the onset; it is a disease that manifests with 
acute fevers, headaches, malaise, and chills (Sarkar, Shah, & Murhekar, 2012).  
Generally the symptoms of malaria appear within 1 week to 2 weeks after infection from 
the anopheles mosquito (Ohnishi et al., 2007).  According to the American Public Health 
Association (APHA), his disease could also take up to 1 year to appear, especially with P. 
vivax and P. ovale infections.  These febrile symptoms are cyclical, and cycle is 
dependent on the kind of parasite.  An infection by P. vivax or P. ovale has a 48 hour 
cycle, P. malariae has 72 hours, but P. falciparum does not cause any cyclic fever which 




severe illness can result within 24 hours of no treatment, and this can be fatal (Anstey, 
Douglas, Poespoprodjo, & Price, 2012).  Adults in malaria endemic areas can develop 
partial immunity (Snow & Marsh, 1998), which is why children and older populations 
develop severe malaria frequently after infection (Griffin, Ferguson, & Ghani, 2014; 
Pistone, Diallo, Mechain, Receveur, & Malvy, 2014; Rizvi et al., 2013).  Some of the 
severe symptoms include anemia, which can be fatal; metabolic acidosis, which results in 
respiratory distress; and cerebral malaria.  Several organs can be affected, which results 
in the fatalities during malaria infection (Lomar et al., 2005).  
Diagnosis 
Prompt diagnosis is necessary for effective management, treatment, and control of 
the transmission of malaria (Tangpukdee, Duangdee, Wilairatana, & Krudsood, 2009). 
Lack of and delay in the diagnosis of malaria affects the treatment, which happens to be 
one of the leading causes of complications and death from malaria infection (WHO, 
2012).  The diagnosis involves the identification of the parasites at the part of the life 
cycle they are in and antigens in the blood of the patient.  Diagnosis can be difficult, 
especially in endemic areas, since there are five different species of the parasite and each 
have a unique product, endemicity, and organism within the life cycle.  Other differences 
include different levels of transmission, signs and symptoms, immunity, and parasitemia 
(Iborra, Garcia, Carrilero, & Segovia, 2013).  The diagnosis can also be difficult in areas 
like the US or other western nations where the disease is not endemic and health care 
personal have little to no experience with the disease (Magill, 2006).  The diagnosis of 




al., Polage et al., 2006,  2013; Reynolds et al., 2013; Stephens, Phanart, Rooney, & 
Barnish, 1999), but clinical diagnosis is the most widely used and the most inexpensive 
form of diagnosis.  This is based on the symptoms and signs of the disease (Maltha & 
Jacobs, 2011), but because the symptoms at the early stage include fever, headache, 
weakness, muscle and abdominal pain, malaise, and vomiting, it is hard to identify a 
specific disease among the many other febrile diseases like bacterial and viral infections 
that also include these symptoms.  There are several algorithms for diagnosis based on 
these symptoms, but these have been shown to be nonspecific (<10%) even though they 
are about 100% sensitive especially in Africa (Perkins et al., 1997).  This could also 
result in over diagnosis of malaria and studies have shown that some of these algorithms 
leads to >30% over diagnosis (Bhandari, Raghuveer, Rajeev, & Bhandari, 2008; Tarimo, 
Minjas, & Bygbjerg, 2001).   
Due to the issue of over diagnosis that occurs in clinical diagnosis, other forms of 
diagnosis like laboratory diagnosis are used, which will complement or confirm the 
clinical diagnosis.  Laboratory diagnosis is based on conventional microscopy and 
technicians will look for the parasites in blood smear which is sensitive and specific but 
requires equipment, good training and time, serological test, which are based on 
antibodies against parts of the reproductive cycle of the parasite and several rapid 
diagnostic tests in the market (Fancony, Sebastiao, Pires, Gamboa, & Nery, 2013;  
Gomes, Espino, Abaquin, Realon, & Salazar, 1994; Maina et al., 2010; Masanja et al 
2010).  Molecular diagnosis of malaria is based on modern molecular biological 




diagnosis of malaria. It has both high sensitivity and specificity (Demiraslan et al., 2013; 
Khan et al., 2013; Morassin, Fabre, Berry, & Magnaval, 2002).  It also requires well 
trained personnel to test.  Moreover, WHO (2012) recommends that suspected malaria 
should be confirmed using laboratory/molecular techniques or rapid diagnostic test before 
initiating treatment.  
Prevention 
The way to prevent malaria infection is to control the life cycle of the plasmodium 
parasite. Since the life cycle is affected by the anopheles mosquito vector, the control of 
the anopheles mosquito is the main way to reduce the transmission of malaria within a 
population. The most popular forms of vector control are through the use of insecticide-
treated mosquito nets (ITNs), indoor spraying with residual insecticides and antimalarial 
medicines. Chemoprophylaxis can also be used especially for travelers and for personnel 
in the military drugs such as mefloquine, doxycycline or atovaquone-proguanil are used 
to  suppress the malaria infections (Grobusch, 2014; Kersgard & Hickey, 2013). Pregnant 
women living in areas endemic to malaria are recommended by WHO to use preventive 
treatment with sulfadoxine-pyrimethamine intermittently after the first trimester during 
their prenatal visits. The same applies to infants living in endemic areas, preventive 
treatment with sulfadoxine-pyrimethamine is recommended with routine vaccinations 
(WHO, 2012). Another important mechanism of controlling mosquitos is the use of 
insecticides. An example was the use of dichlorodiphenyltrichloroethane (DDT) which 
was used to eradicate malaria in the US and parts of Europe but was ban by the WHO due 




insecticides both indoor and outdoor used to kill the adult mosquitos has been shown to 
be effective especially if it is combined with other preventative measures like mosquito 
nets and chemoprophylaxis (Kigozi et al., 2012). Mosquitos are growing resistance to 
some of the common insecticides like the pyrethroids, which are the class of insecticides 
mostly used for ITNs (Gatton et al., 2013; Hewitt, Delacollette, & Poirot, 2013).  
Treatment/Management 
It is important to note that malaria is fully preventable and treatable, and treatment 
or management of malaria is necessary for the control and elimination of the disease. The 
prompt treatment of malaria is part of the secondary prevention, which reduces the 
transmission and spread of the disease (Band et al., 2013).  Effective treatment can also 
reduce drug resistance since it reduces the frequency of mutation of the parasite. As 
mentioned before, lack of treatment can cause very serious complications. Additionally, 
ineffective treatment can make matters even worse as it increases the population of 
resistive strains, which makes the disease difficult to treat as it renders current 
medications ineffective (Tordrup, Virenfeldt, Andersen, & Petersen, 2011). One such 
drug is chloroquine which was very effective as mono-therapeutic drug for both 
complicated and uncomplicated malaria (Tonnesmann, Kandolf, & Lewalter, 2013). Until 
recently, chloroquine was the prototypic drug due to its effectiveness; it is very cheap, 
has the best safety profile compared to other antimalarial drugs and one of the most 
studied (Pfeiffer et al., 2008).  Unfortunately, it is not effective in many endemic areas 
and may not be recommended for treatment in most of these areas even though it is still 




malaria treatment and management addresses the treatment of the disease, monitoring of 
parasitic drug resistance, chemoprophylaxis and reduction of the spread of the parasite. 
There are several antimalarial medications, and most of these have been in existence for 
many years. The WHO (2012) advises against the use of any form of mono-therapy for 
the treatment of malaria. It recommends combination of at least two active ingredients 
with different mechanisms of actions.  This could be one drug with these ingredients or 
combinations of drugs. The WHO highly recommends artemisinin-based combination 
therapies (ACTs).  There are five ACTs currently recommend by WHO, and the choices 
of which combination is normally based on  therapeutic efficacy studies (WHO, 2012).  
Antimalarial Medications 
 Most of the antimalarial drugs are active against different parts of the life cycle of 
the parasite. The most common medications include quinine and it agents, chloroquine, 
amodiaquine, pyrimethamine, proguanil, sulfonamides, mefloquine, atovaquone, 
primaquine, artemisinin and its derivatives, halofantrine, doxycycline and clindamycin. 
The most common non-artemisinin based combination therapies are sulfadoxine-
pyrimethamine, pyrimethamine and chloroquine, pyrimethamine and lumefantrine, 
pyrimethamine and mefloquine. The most common artemisinin-based combination 
therapies (ACTs) are artemether and lumefantrine, artesunate and amodiaquine, 
artemether and mefloquine, artemether and sulfadoxine/pyrimethamine, 
artesinin/piperaguine/primaquine and dihydroartemisinin-piperaquine (Deye et al., 2012; 
Fryauff et al., 2007; Leggat, 2012;  Newton et al., 2011; Njau et al., 2013; Osei-Akoto, 




et al., 2013; Tsiamis, Piperaki, & Tsakris, 2013; Wasnik, Manohar, Humaney, & Salkar, 
2012). 
Antimalarial Drug Policy in Ghana 
According to the Ministry of Health of Ghana (2009), there have been several 
initiatives to roll back malaria for many years mostly with the help of the WHO. 
Unfortunately, malaria is still endemic in Ghana, and it is still the number one cause of 
death and mortality in Ghana. Like other countries, the control of malaria in Ghana also 
suffers from the development of drug resistance by the plasmodium parasites especially 
from monotherapy. Because of this, Ghana went in line with WHO’s antimalarial use of 
ACT based recommendations for all countries. Based on this, artemether-lumefantrine is 
used in Ghana for uncomplicated malaria. Other alternative artemisinin combinations 
recommended for uncomplicated malaria are artemether/ lumefantrine and 
dihydroartemisinin/piperaquine combinations. Quinine is used for treatment failure and 
complicated malaria. Intramuscular artemether can also be used for complicated malaria. 
Similar to most countries, monotherapy is not recommended in Ghana (Ministry of 
Health, 2009).  
General Epidemiology of Malaria 
The intensity of malaria transmission depends on factors related to the parasite, 
the mosquitos, the human host, and the environment. There are several ways malaria is 
transferred to humans. The most common way of malaria transmission especially in areas 
endemic to the infections is through the bite of the anopheles mosquito also known as the 




exclusively through the bites of Anopheles mosquitoes. A small subset of these is the 
imported malaria, which is a factor in countries that have already eradicated malaria. 
These can also cause “Airport" Malaria. This is when mosquitoes are transported by 
plane from one country to the other (from an endemic to a non-endemic country). The 
other kind of malaria is the Congenital Malaria. In congenital malaria, infected mothers 
transmit parasites to their child during pregnancy before or during delivery. This is very 
common in immigrants and refugees (CDC, 1981; Tittle et al., 1982).  
Transfusion-Transmitted Malaria is  generally very rare, but since malaria is a 
blood borne disease there is always a potential of it getting transmitted during blood 
transfusion, organ transplantation and even shared needles (Ozkurt, Erol, Kadanali, 
Altoparlak, & Tasyaran, 2005; Rojo Medina, 2014). There is still no approved way to 
screen for malaria parasites in donated tissues; this is partly because most tests are not 
that sensitive. Even though this is rare, Transfusion-Transmitted Malaria can be common 
in places endemic with malaria because malaria screening is still not performed in many 
of these countries even though it is recommended by international policies (Owusu-Ofori, 
Parry, & Bates, 2010) 
According to the WHO (2013), in 2010 there was an average of about 220 million 
cases globally with over 650,000 estimated deaths.  Most of these deaths (91%) came 
from Africa, and a majority of the deaths globally (86%) came from children under 5 
years of age. This shows that malaria is still a big health problem. Majority (91%) of the 
malaria cases were due to P. falciparum infection (WHO, 2013). Death caused by malaria 




Saharan Africa. Even though majority of the prevalence rate of malaria is in Africa, the 
disease burden and trends vary widely across the continent. The disease burden in the 
southern African countries is much better than the rest of the continent (Cibulskis et al., 
2007; Griffin et al., 2014). 
Populations at Risk  
As mentioned earlier, malaria is endemic in sub-Saharan Africa, but it is also 
prevalent Latin America, Asia, Middle East and some parts of Europe but in relative 
terms, it is not as much as the sub-Saharan regions of Africa (Haq, Mahjour, & Khan, 
2013; Makdoembaks & Kager, 2000; Vanderelst & Speybroeck, 2013; Yasuoka & 
Levins, 2007). According to the WHO (2013), almost 100 countries and territories had 
populations with ongoing malaria transmission. Out of all the populations, young 
children, older populations, immune-incompetent patients and pregnant women have the 
highest risk of complications from the infections.  
Malaria Epidemiology in Ghana 
Even though there are differences between the regions in Ghana with the northern 
part being mostly savanna and middle/southern part being the rain forest, the malaria 
endemic is still very high in all regions. The disease burden of malaria is still very high in 
Ghana with almost 350 cases reported per 1000 of cases among young children below the 
age of 5 (Asante et al., 2011). With all the effort to eradicate or decrease the incidence 
and prevalence rate of malaria, there is little to no evidence that there has been a decrease 
in the percentage of hospital admission and death from malaria in recent years (WHO, 




with almost 100% of the population being at risk for infection (WHO, 2011).  This is not 
different from most of the other West-African countries. The transmission is mostly due 
to P. falciparum. It is also worth noting that most of the data collected is based on 
hospital admissions and deaths, there are a lot of people who go under the radar 
especially through self-medication (WHO, 2011). In one study carried out in the rain 
forest area of the country, there were approximately 270 infective mosquito bites per 
person per annum. In another study, it was found that prevalence rate of the malaria 
infection was > 50% especially among children < 5 years. Children < 5 years of age had 
at least 7 episodes of malaria infection per year (Owusu-Agyei et al., 2009). 
Counterfeit Drugs 
The WHO (2011) cited the Black's law dictionary, when it tried to define 
counterfeit drug. A counterfeit drug was defined as an imitation of drug prepared without 
the rights or permission from the original manufacturer with the intention of deceiving 
and scamming consumers (WHO, 2011). The problem is that there is not a universally 
accepted definition and theses definitions vary from country to country. Each country or 
organization has its own definition. For instance, the US Food and Drug Administration 
(USFDA) define a Counterfeit medicine as a fake medicine, which could contain the 
wrong active ingredient or the right ingredient contaminated or right active ingredient, 
but the WHO defines a counterfeit as a drug whose identity and source has been 
deliberately mislabeled. Counterfeit drugs have a wide spectrum which includes drugs 




sub-therapeutic amounts of active ingredient (Attaran et al., 2012). A sub-therapeutic 
drug has the correct ingredient, but the amount of drug is less than the labelled amount.  
Factors That Fuel Counterfeit Drugs 
Generally, this has to do with economics. As mentioned earlier, there are millions 
of dollars of profit being made from these drugs. Producing good quality drugs come 
with a price. It cost billions of dollars to come out with one drug; therefore, falsifying 
drugs has been dubbed a “the perfect crime” because it is very profitable, and it costs 
much less to make (Dondorp et al., 2004). Another problem is from tiered productions 
where companies make inferior drugs to inferior markets due to lack of enforcement and 
less stringent regulations, and it is mostly described as legal. This is basically exploitation 
by some companies; they produce lower quality drugs, which fit in the definition of 
counterfeit drugs (Caudron et al., 2008). These systems tie into the weak regulatory 
systems; countries with high levels of counterfeit drugs have very weak regulatory 
authorities (Dondorp et al., 2004). The WHO found that in sub-Saharan African countries 
most of these organizations have no legal authority to perform inspections. As a result,  it 
made it easier for counterfeit medicines to infiltrate the market (Zumoff, 2007). For 
instance in 2007,a Chinese regulator through corruption and bribery issued several 
fake/forged in one of the provinces (Liu, 2010). Another important factor is the lack of 
awareness and Action. Without a clear idea of the extent of the counterfeit problem, it is 
difficult to come with the appropriate intervention strategies. The awareness of the 
problem is very low in many of those countries even though it is beginning to become an 




very little knowledge of the extent of the problem (Cockburn, Newton, Agyarko, 
Akunyili, & White, 2005). 
Finally, a big problem is the disease burden in these developing countries, 
combined with extreme poverty, bad health care systems (Wang et al., 2014). People 
have no choice but to go for cheap medication, cut corners, which opens patients up to 
counterfeits drugs. Socioeconomic factors play a major role in this (Krefis et al., 2010).  
Assessment of the Global Counterfeit Antimalarial Drug Problem 
The extent of counterfeit drug globally is not known since there has not been a 
study that looks at this problem globally. Nevertheless, it is a problem that affects almost 
every country rich or poor; but, it has a worse adverse effect on poorer countries 
(Caudron et al., 2008). According to the CDC (2013), it is estimated that 10% to 30% of 
all medicines sold in the developing world are counterfeit. This is estimated to be 1% in 
the industrialized countries. One question that begs asking is whether the problem with 
counterfeit drugs has either been ignored or underestimated because it is becoming 
crucial public health problem for malaria and other diseases (Newton et al., 2008). 
Financially, even though it creates a burden on these countries, the manufactures have 
lots to gain because it is very lucrative with an estimate of  >15% of pharmaceutical sales 
worldwide with most of it (>60%) in developing countries (Newton et al., 2006)    
A report from the Institute of Medicine (2013) says that according to a consortium 
of major drug companies, counterfeit drugs were sold in more than 124 countries in 2011 
alone. Several studies on counterfeit drugs have been conducted in many countries 




medications. Majority of these studies were on antimalarial medication and 
antimicrobials in general (Newton et al., 2011). Majority of these counterfeit medications 
are in sub-Saharan Africa ranging from about 12% to 50 %. South eastern Asia follows 
very closely with range with about 10 to 40% (Almuzaini, Sammons, & Choonara, 2013). 
Amin and Kokwaro (2005) studied the quality of sulphadoxine-pyrimethamine 
(SP) and lumefantrine (LMFT) drugs given as over the counter medication (OEM) 
communities Kenya. These drugs are OEM because most people self-medicate after 
infection.  They found that about 45% of SP and 33.0% of LMFT were counterfeit 
(Amin, Snow, & Kokwaro, 2005). A cross sectional survey to access pharmacies selling 
antimalarial drugs in Southeast Asia (Laos, Myanmar, Vietnam, Thailand and Cambodia) 
found that 53% of the tablets did not contain the right antimalarial medications.  Four 
years later, collaborative investigation into the counterfeit artemether in South East Asia 
was carried out involving countries including Vietnam, Laos, Cambodia, Thailand and 
Myanmar. Several professionals were involved including chemists, palynologists, police, 
healthcare personnel and criminologists with the coordination from International 
Criminal Police Organization (INTERPOL). Using High Pressure Liquid 
chromatography, the investigators confirmed that almost 50% of artemether drugs were 
counterfeit (Newton et al., 2008). This is a huge problem in mainland Asia and the same 
issue applies in Africa, as most of these counterfeit drugs are shipped from Asia (Newton 
et al., 2011). 
Developing countries like Ghana lack well established regulatory organizations; 




malaria (Barimah & Mensah, 2013; Kassebaum et al., 2014). Ghana has grappling 
challenges in healthcare with millions of people lacking access to health care and most 
people relying on local stores, medicine men and women, pharmacies and licensed 
chemical sellers for medical advice and treatment. The lack of effective heath care makes 
the system very vulnerable and easy for counterfeit medication to infiltrate the market. In 
recent years, there has been some coverage about counterfeit antimalarial dugs in Ghana, 
and the awareness was raised because it directly affected an influential person. (Daily 
Guide, 2013). It is believed that majority of the counterfeit medication comes from South 
east Asia (Bate & Hess, 2010). But the extent of counterfeit medication is not known 
except for a few publications in a few small towns in Ghana (Asuamah et al., 2013; Bate 
& Hess, 2010).  
Previous Work on Counterfeit Medication in Ghana  
There have been very few studies looking at the quality of the medication in 
Ghana. A pilot study conducted in 2013 looked at the quality of artemether and 
Lumefantrine tablets in a fishing village in an attempt to look at the quality in fishing 
villages in Ghana (Affum et al., 2013). The researchers randomly sampled blister packs 
of antimalarial tablets from a small fishing village. They used protocols from the 
International Pharmacopoeia and Global Pharma Health Fund Minilab (IPGPM) to assess 
the quality of the tablets, and the analytical procedure used was High Pressure Liquid 
Chromatography (HPLC). They found that 17% of the drugs they tested had quality 
issues (Affum et al., 2013). The advantage of doing this is that it was pilot project, so 




anything about the counterfeit problem in Ghana as a whole. In the assessment of 
counterfeit medication in Ghana, the different outlets have to be taken into 
considerations. The main outlets include drugs sold by the government hospitals, the 
large pharmacies and the small scale licensed chemical sellers (FHI360, 2013). The 
demographics of fishing and non-fishing communities may be different, so it may be 
important to have a larger size sample covering different groups and demographics. 
There are studies that show that the antimalarial behaviors between different regions are 
different. For instance, behavior between urban centers and villages were different, and 
this could affect the extent of counterfeit medication (Gardiner, Biggar, Collins, & 
Nkrumah, 1984). Another study looked at substandard and falsified anti-tuberculosis 
drugs in 19 cities in Africa, Asia and South America. Ghana was one of the countries in 
Africa that was tested. This study was not focused on Ghana so the sample size in Ghana 
was very small, which does not inform us about the whole country. Once again, it did not 
take into consideration the different ways that people acquire their medication in Ghana 
(Bate, Jensen, Hess, Mooney, & Milligan, 2013).  Bate, Coticelli, Tren, and Attaran 
(2008) also studied the quality of antimalarial medication in six countries including 
Ghana, Kenya, Nigeria, Rwanda, Tanzania and Uganda. They studied several 
antimalarial drugs and found that on the average 35% of the drugs were counterfeit. 
Because they were using many countries and several antimalarial drugs, they had very 
few samples in each cohort. They sampled only 37 tablets from Ghana, which is quite 




Stanton et al. (2012) looked at the quality of uterotonic drugs in Ghana. Ampules 
were purchased from three districts with different characteristics in Ghana; these were 
coastal, forest and savannah districts. They found that most (86% to 100%) of the 
different drugs did not meet the quality standards set by WHO.  This study did not take 
into consideration the vast difference in the demography within these regions, the 
population differences and difference between the various points of sales (Stanton et al., 
2012). Bate and Hess (2010) looked at the quality of antimalarial drug quality in Accra 
and Lagos, which are the capital cities of Ghana and Nigeria respectively. In this study, 
the percentage of counterfeit drugs in Ghana ranged from 54% to 94% depending on the 
method used to check the quality of the drug. The researchers used what they called a 
visual method and analytical tests using Raman spectrometer.  The problem with this 
study is that they focused their sampling at the capital city only and their sampling 
method was only from private pharmacies. Only 18 pharmacies were sampled in Ghana 
(Bate & Hess, 2010). There are 429 pharmacies and 9210 licensed chemical sellers in the 
country (FHI360, 2013), any study being done in Ghana should statistically represent 
these outlets.  Most of these studies used high pressure liquid chromatography (HPLC) as 
the analytical techniques used to measure the concentration of the drug.   
Conclusions 
Malaria is still endemic in many places especially in the sub-Saharan region of 
Africa. There are several medications that can be used for the treatment and prevention 
the disease. Unfortunately, there are studies and reports that show that some of these 




been done to check the quality of drugs especially antimalarial drugs. Ghana is one of the 
countries with very high rates of malaria infection.  A literature review shows very few 
studies attempting to assess the quality of drugs in Ghana. Majority of these studies were 
not comprehensive enough.  The data were not comprehensive, most were pilot studies, 
which focused on very small populations. Sampling seemed arbitrary with no statistical 
basis on how the populations were selected. Most of the research studies were all focused 
on small regions in the country, which did not tell us much about the quality of drugs in 
the whole country. The previous studies showed vast variability of the results, which did 
not substantiate a systematic pattern for arriving at a conclusive state. They range from 
hardly any counterfeit drugs to almost 90% of the drugs being counterfeit. Most of the 
sampling done for these studies was from samples collected from retail outlets. None of 
studies considered the different kinds of retail outlets used in Ghana. Therefore, there is a 
need for a more comprehensive study that provides a quantitative and systematic 





Chapter 3: Research Method 
Introduction 
In this chapter, I will address the research design, rationale of the research, and 
the study variables.  I will also evaluate the target population, sampling procedure, and 
the instrument for analysis in addition to providing operationalization of variables and 
assessing the data analysis and threats to validity.  Next, I will identify the software for 
analyses and evaluate possible ethical concerns.  Finally, I will summarize the design and 
methodology. 
Study Purpose 
There are several medications in the market used for malaria treatment.  It is 
believed that most of these drugs are counterfeit.  Unfortunately, the areas suffering most 
from malaria seem to have a higher prevalence of counterfeit medication.  Any 
eradication program will have to include reducing or eliminating counterfeit medication 
in the systems. Because there is no data quantifying the percentage of these drugs that are 
counterfeit, the purpose of this study was to empirically assess the poor quality of 
antimalarial drugs in Ghana.  I did this by investigating the most popular or prescribed 
antimalarial tablet artemether-lumefantrine, as this tablet is recommended by the Ghana 
Ministry of Health (2009) as the first line for uncomplicated malaria. 
Research Design and Rationale 
This was a cross sectional correlational study that qualifies as quasi-experimental 
due to lacking a control group, which is a part of what makes a study experimental.  The 




investigate possible sources of the variation in quality in Ghana.  The actual amount of 
active ingredients of the two most prescribed antimalarial drugs, artemether and 
lumefantrine, were compared to the expected or labeled amount.  This study required 
systematic measurement of study samples in the lab using validated analytical techniques.  
As Fowler (2009) describes, the quantitative method is the best way to assess a situation 
or problem analytically, which is why it was used in this study. According to Creswell 
(2009), one of the hallmarks of quantitative methodology is the analytical part of the 
study; for this study, the analytical part was the quantitative measurements used to 
determine the relationship among the variables.  It is also important to point out that this 
study was not intended to prove a causal relationship; rather, it is descriptive.  The aim of 
the study was to empirically define the problem with the quality of antimalarial drugs in 
Ghana, as empirical knowledge of the problem can provide a sustainable way of finding a 
solution.  
Study Variables 
The study variables were the concentration of artemether and lumefantrine, which 
is measured in milligram per milliliter of solution.  These were the dependent variables as 
shown in Table 1.  The independent variables are the pharmacies, LCS, and their 
locations.  This includes those acquired from private and government run pharmacies in 
cities, small towns, and wholesale companies (Table 1). It was also important to see if the 
cost of the drugs was different and if it had an effect on the other study variables. This 




Table 1  
Study Variables 
Dependent 
Concentration of artemether (mg/ml) 
Concentration of lumefantrine (mg/ml) 
Independent 
Private pharmacies  
Cities that the private pharmacies are locates 




Cities that the LCS are located 
Small towns and villages are located 
mPedigree scratch-off panel 
Covariate Cost of Drugs 
 
Target Population 
I examined artemether-lumefantrine combination tablets, which in Ghana can be 
obtained in two formalized ways: traditional pharmacies with a trained pharmacist and 
licensed chemical sellers (LCS). LCS sell drugs mostly in suburbs small town and 
villages, with no supervision of a pharmacist, but are licensed by the government to sell 
over-the-counter medication and common medications authorized by the government.  
Because these are not well controlled or monitored, the LCS sells almost the same 
medications sold by the pharmacies.  
The tablets were obtained from a variety of locations in Ghana.  A majority of the 
pharmacies are in the major cities within ten regions.  According to the Ghana Pharmacy 
Council, there are 430 Pharmacies and 9,210 Licensed Chemical Sellers throughout the 




has about half (233), Kumasi has (79) pharmacies, and 40 are in the other 2.  The LCS 
are more spread out as they serve more remote and rural communities. 
Sampling Procedures 
 Stratified sampling was used to group and sample the population of the town or 
city based on the pharmacies per population density.  For the sampling of the licensed 
chemical sellers, simple random sampling was used.  In addition, for the pharmacy stores, 
after the stratification method was done, simple random sampling was used.  The goal of 
the study was to have a power of .08 (80%), with a Cohen specification of a large effect 
size of 0.5 for pharmacies and medium effect size of 0.3 for LCS.  For each hypothesis, a 
95% confidence with the alpha level (type 1 error) set to 0.05 (5%) was assumed.  Using 
Gpower 3.1 software, the total number of observation in this study was 141.  This 
represented 32 pharmacies and 109 LCS.  The numbers of samples that represented 
pharmacies and LCS found in the cities were 16 and 39 respectively.  The numbers of 
samples that represented pharmacies and LCS found in small towns/villages were both 
16, and the number samples for local and imported drugs were 141 each.  The total 
number of samples representing local and government sources was 141 and 16 (from 10 
regional and 6 district capital towns) respectively.   
Table 2 below shows the number of pharmacies with their samples for each 
stratum and Table 2 and Table 3 show the towns that were randomly picked for sampling 
of the pharmacies.  Half of the samples were from the cities and the other half from small 
towns/villages, as LCS are more spread out as they serve more remote and rural 




pharmacies (Table 3 and Table 4), and the other half was from towns/villages with no 
pharmacies (Table 5).  Inclusion criterion for pharmacies was that they were stores run by 
registered pharmacists as defined by the Ghana pharmacy board; exclusion criterion for 
pharmacies was that they were LCS and stores without registered pharmacists.  Inclusion 
criterion for LCS was that they were stores without registered pharmacists; exclusion 
criterion for LCS was that they were pharmacies and stores with pharmacists.  The 
government-run pharmacies are located in mostly in the cities and the bigger towns.  
Each Region has an average of four government-run hospitals or clinics; sampling was 
done from two of the hospital pharmacies in each region.  Cities like Accra and Kumasi 
with many pharmacies and LCS will have their sampling done by taking samples from 





Table 2  
Number of Private Pharmacies in Ghana by Town/City  





Agona Swedru 1 












































Table 3  
Number of Pharmacies and LCS Sampled by City 
City 
Number of 
Pharmacies Number of LCS 
Accra 7 23 
Cape Coast 1 1 
Koforidua 1 1 
Kumasi 3 10 
Sekondi-Takoradi 1 1 
Sunyani 1 1 
Tamale 1 1 






Table 4  
Number of Pharmacies and LCS Sampled by Small Town/Village 
Small Towns /Villages 
Number of 
Pharmacies Number of LCS 
Agogo 1 1 
Agona Swedru 1 1 
Akim Oda 1 1 
Anloga 1 1 
Bawku 1 1 
Bolgatanga 1 1 
Effiakuma 1 1 
Kintampo 1 1 
Konongo 1 1 
Mampong 1 1 
Nkawkaw 1 1 
Savelugu 1 1 
Suhum 1 1 
Wa 1 1 
Wenchi 1 1 






Table 5  
Number of LCS in 10 Regions in Ghana with No Pharmacies  
Region Towns Number of LCS 





















































Research Questions and Hypotheses 
It may not be possible at this time to detect all the counterfeit medication in 
Ghana, and we may not be able to detect it for ATMT and LMFT either.  However, we 
can find out the minimum percentage of artemether and lumefantrine in Ghana that is 
counterfeit, and which are good predictors of the quality antimalarial medication.  Four 
research questions and hypothesis were used to investigate this:  
 RQ1: Is there a difference between the percentage of counterfeit medication in 
pharmacies found in the cities and those found in the rural areas? 
Ho1: There is no significant difference between the percentages of counterfeit 
medication in pharmacies found in the cities versus those found in the rural areas. 
Ha1: There is a significant difference between the percentages of counterfeit 
medication in pharmacies found in the cities versus those found in the rural areas. 
RQ2: Is there a difference in the percentage of counterfeit drugs between 
pharmacies and licensed chemical sellers? 
Ho2: There is no significant difference in the percentage of counterfeit drugs 
between pharmacies and licensed chemical sellers. 
Ha2: There is a significant difference in the percentage of counterfeit drugs 
between pharmacies and licensed chemical sellers. 
RQ3: Is there a significant difference in the percentage of counterfeit drugs 
between those drugs imported and drugs locally manufactured? 
Ho3: There is no significant difference in the percentage of counterfeit drugs 




Ha3: There is a difference in the percentage of counterfeit drugs between those 
drugs imported versus drugs locally manufactured. 
  RQ4: Is there a correlation between the mPedigree scratch-off panel on the 
packaging and percent of counterfeit drugs? 
Ho4: There is no significant difference between the mPedigree scratch-off panel 
on the packaging and percent of counterfeit drugs. 
Ha4: There is a significant difference between the mPedigree scratch-off panel on 
the packaging and percent of counterfeit drugs. 
Instrumentation and Operationalization of Constructs 
Operationalization  
In order test the hypotheses, the variables had to be identified and defined.  The 
operational definitions of the variables are in Table 6. 
Table 6  
Variable Type Variable Operational Definition 
Dependent 
Concentration of 
artemether (mg/ml) The concentration of the artemether and lumefantrine 
represents the amount of drug per unit volume of water. This 
will allow us to compare the various amounts on the drugs on 
the same scale and units. 
Concentration of 
lumefantrine (mg/ml) 
Independent Private pharmacies  
Private pharmacies (stores run by at least one registered 
pharmacist) in cities. 






Variable Type Variable Operational Definition 
Independent  Cities 
Cities are defined as urban communities that have utilities, 
public transportation, modern sanitation, large population 
density, and businesses.    
  
Small towns and 
villages 
Small towns and villages lack some or all utilities like pipe 
born water, public transportation, modern sanitation and 




Licensed chemical sellers (stores not run by registered 




The mPedigree scratch-off panel, is intended to protect against 
counterfeit medication by labeling medication using unique 
codes, which are verified by SMS. The code is sent via SMS to 
a global hotline for verification. A response is sent back within 
seconds to confirm or deny the authenticity of the drug  
Covariate Cost of Drugs 
The cost of the medication may affect the quality of the drug. 
The cost of every table will also be recorded and tracked to see 
if it is a possible covariate.  
 
Data Collection 
In order to test samples, data was collected from the various kinds of retail stores 




Determination of the concentration of artemether and lumefantrine  
The concentration of artemether and lumefantrine was determined using High 
Performance Liquid Chromatography (HPLC).  This was performed at the Mayo Clinic 
Pharmacology Shared Resource Center in Rochester, MN.  This lab is a certified lab that 
pharmacologic expertise, methodologies, and services especially for phase I and II trials 
funded by the National Cancer Institute (NCI).  This removed the complication of dealing 
with customs and shipping these drugs to the US for measurement.  They have several 
years of experience developing, approving, and validation methods for testing the 
concentration of drugs for clinical trials.  HPLC is an analytical method used for 
separating mixtures and quantitation the amount of the analytes in the mixture.  It is the 
method recommended by the US Food and Drug Administration (USFDA) for checking 
drug concentration, and it is used by pharmaceutical companies, toxicologists, and 
pharmacologists.  The basic principle of chromatography is the separation of mixtures 
based on the speed of movement through a medium.  After the sample goes through the 
medium, a detector will measure the fluorescence, or the wavelength emitted by each of 
the analytes, which is quantified.  These tests are confirmed using standards and controls 
and quantified using calibration curves from these standards.  The assay was based on 
validated assays used by others and implemented by the African National Quality Control 
Laboratories (Gaudin et al., 2009; Gu, Li, Melendez, & Weina, 2008).  The separation of 
the mixtures was achieved by using column (100 × 4.6 mm, 3μm) as a stationary phase 
and a binary gradient using a liquid phase (aqueous phase) containing phosphate buffer at 




the stationary phase, which allows the drugs to separate based on the chemical properties, 
the partition coefficient between the drugs and the column bed.  These processes and 
methodology were validated and has been accepted by the USFDA as the guideline in 
order to ensure its robustness, specificity, accuracy and precision are achieved (Geditz et 
al., 2014; Houstoun et al., 2014). HPLC grade (>99%) artemether and lumefantrine were 
be purchased from Fisher Scientific to create standards and quality controls (Fischer 
Scientific, 2016). This dissolved in fixed volumes of 20% water and 80% acetate buffer 
PH 4.5 (buffer A) to make the calibration standards. The concentrations were measured 
in mg/ml. The tablets were also dissolved in 10mls buffer A. These were vortexed and 
centrifuged at 3500 rpm for 5 mins. The supernatant was decanted into a 96 well filter 
plate before he samples were analyzed. These samples also included standards and 
controls per good lab practice based on the code of federal regulations title 21 (U. S. 
Food and Drug Administration, 2016) and the Guidance for Industry, Analytical 
Procedure and Methods Validation for Drugs and Biologics (U. S. Food and Drug 
Administration, 2001).      
Analysis Plan 
After all the data is collected, and the samples have been evaluated, the data was 
imported into the Statistical Package, SPSS version 21, for further analyzes. The data was 
exported from the instrument and verified to maintain the integrity and validity of the 
data. The data collected from analyzing the concentrations of artemether and 
lumefantrine in the lab using the HPLC system was entered into the SPSS spreadsheet to 




conducted using descriptive statistics. Categorical variables were described using 
frequencies and the continuous variables were examined using means and standard 
deviations (Table 7). Possible Relationships between categorical independent variables 
was tested using cross-tabulations with Pearson’s χ2 (Table 7). Multiple linear 
regressions will also be used to assess the associations between the variables. The 
probability of the distribution of the concentration of artemether and lumefantrine 
concentrations was described using histograms.  
Table 7.  
List of Variables and Analyses 
Type of Variable Descriptive 
Covarian
ce 
   




























Concentration of lumefantrine (mg/ml) in private 





Concentration of lumefantrine (mg/ml) in private Small 










Concentration of lumefantrine (mg/ml) in LCS in Small 















Type of Variable Descriptive Covariance 
      
Cost of Drugs  
Means and 
SDs ANOVA's 
Correlation between Cost of Drugs and 
pharmacies in Cities 
Correlation 
coefficient (r) ANOVA's 
Correlation between Cost of Drugs and LCS in 
Cities 
Correlation 
coefficient (r) ANOVA's 
Correlation between Cost of Drugs and 
pharmacies in small towns/villages 
Correlation 
coefficient (r) ANOVA's 
Correlation between Cost of Drugs and LCS in 
small towns/villages 
Correlation 
coefficient (r) ANOVA's 
      














Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   















Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   




Number (Percent) of counterfeit artemether in all 
LCS 
Continued on next page 





Type of Variable Descriptive Covariance 





Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   





Number (Percent) of counterfeit artemether in 




Number (Percent) of counterfeit lumefantrine in 




Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   
Number (Percent) of counterfeit Drugs in Small 




Number (Percent) of counterfeit artemether in 




Number (Percent) of counterfeit lumefantrine in 




Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   















Number (Percent) of Drugs with Correct 
concentration in City Pharmacies 








Type of Variable Descriptive Covariance 
   
Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   















Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 




   










Number (Percent) of Drugs with Correct 




Number (Percent) correct lumefantrine 




Number (Percent) correct artemether 





Below is a summary of the research questions: 
1) RQ1 - Is there a difference between the percentage of counterfeit medication 
in pharmacies found in the cities and those found in the rural areas? Was 




2) RQ2 - Is there a difference in the percentage of counterfeit drugs between 
pharmacies and Licensed Chemical Sellers? Was tested using Crosstabs with 
Pearson’s χ2. 
3) RQ3 - Is there a significant difference in the percentage of counterfeit drugs 
between those drugs imported and drugs locally manufactured? Was tested 
using Crosstabs with Pearson’s χ2. 
4) RQ4 – Is there a significant difference in the percentage of counterfeit drugs 
between drugs with scratch codes and those without scratch codes? Was tested 
using Crosstabs with Pearson’s χ2. 
Threats to Validity 
There is the need for an evidence of validity and reliability for the study 
especially during interpretation phase (Trochim, 2006).  Therefore, a very specific and 
sensitive assay to ensure the data accuracy was used as well as using a logical approach 
to explain the problem and any dependent resolution to the problem statement.  One of 
such methodologies is the use of Construct validity.  Construct validity addresses whether 
the results are what they are supposed to be for the research or if what was done was what 
it was intended to do (Fowler, 2009).  It deals with how the variables were 
operationalized and if they are related to the theory of the study. This was prevented from 
happening with the use a validated HPLC assay, which is also the assay used for similar 
studies. Another problem is the possibility of Internal validity issues, which mainly deals 
with how the experiment was conducted and if it has an effect on the outcome (Fowler, 




variables is not performed correctly, this could lead to the wrong conclusions.  
Consequently, it could raise questions about conclusion validity. With a power of .08 
(80%), the goal is to reduce this possibility. Another threat to external validity is the fact 
that the conclusions drawn from this study should hold for the whole country. The goals 
are to use the correct statistics to prevent this from happening.  A limitation of this study 
is that it is not providing any relationship or possible cause and effect between the 
variables (Creswell, 2007). 
Ethical Procedures 
Approval from the Walden University Institutional Review Boards (1-06-15-
00041987) was obtained prior to data collection. I will observe all research ethics during 
the primary data collection of this research. I will follow the ethical principles of the 
Belmont Report. The confidentiality of the pharmacies and LCS was protected by not 
revealing their names when the data is being processed.  Each store was given a unique 
identification code, and this code will in a separate, secure location from the data files. 
All data was kept under password protection. Because these drugs could cause harm to 
the patients that buy them, any retail store that is found to have counterfeit drugs was 
reported to the Ghana food and drug administration (GFDA).  The GFDA for the quality 
of all drugs distributed in Ghana. It has the right to prosecute and arrest perpetrators. It 
has been on high alert due to the incidence suspected counterfeit drugs in the Ghanaian 
market. It was my ethical duty to report any such occurrences especially because I will 





This chapter focused on the use of quantitative experimental research 
methodology in this research investigation. The rational of the study is to assess the 
quality of antimalarial medication in Ghana by empirically comparing the actual amount 
of active ingredients of the two most prescribed antimalarial drugs, artemether and 
lumefantrine, to the intended or labelled amount. These drugs were purchased from retail 
stores in Ghana from various towns and cities, and measured using a HPLC to compare 
the actual versus expected concentrations. The various topics included in this chapter 
were study design, rational, study variables, target population, sampling and sampling 
procedures, eligibility criteria, research questions and hypothesis, study variables 
description and instrumentation, determination of the concentration of artemether and 
Lumefantrine, sampling, ethics and threats to validity. Included in this chapter is a 
description of my statistical analysis of the data. In Chapter 4, the results the study was 





Chapter 4: Results  
Introduction  
The purpose of this quantitative study was to explore the extent of antimalarial 
counterfeiting by looking at the percentage of ATMT and LMFT in drugs sold in retail 
outlets in Ghana that is counterfeit.  The following are the research questions of this 
study: 
RQ1 - Is there a difference between the percentage of counterfeit medication in 
pharmacies found in the cities and those found in the rural areas? 
Ho1: There is no significant difference between the percentages of counterfeit 
medication in pharmacies found in the cities versus those found in the rural areas. 
Ha1: There is a significant difference between the percentages of counterfeit 
medication in pharmacies found in the cities versus those found in the rural areas. 
RQ2 - Is there a difference in the percentage of counterfeit drugs between 
pharmacies and Licensed Chemical Sellers? 
Ho2: There is no significant difference in the percentage of counterfeit drugs 
between pharmacies and Licensed Chemical Sellers. 
Ha2: There is a significant difference in the percentage of counterfeit drugs 
between pharmacies and Licensed Chemical Sellers. 
RQ3 - Is there a significant difference in the percentage of counterfeit drugs 
between those drugs imported and drugs locally manufactured? 
Ho3: There is no significant difference in the percentage of counterfeit drugs 




Ha3: There is a difference in the percentage of counterfeit drugs between those 
drugs imported versus drugs locally manufactured. 
 RQ4 – Is there a correlation between the MPedigree scratch-off panel on the 
packaging and percent of counterfeit drugs? 
Ho4: There is no significant difference between the MPedigree scratch-off panel 
on the packaging and percent of counterfeit drugs. 
Ha4: There is a significant difference between the MPedigree scratch-off panel on 
the packaging and percent of counterfeit drugs. 
In this chapter, I will present the results of the study and descriptive statistics of 
each variable, relationships among variables, and analyses conducted to examine the 
research questions and hypotheses.  In this study, alpha was set to .05, which means that 
p-values less than .05 were considered statistically significant. 
Data Collection  
Divergence in data collection from the research plan presented in Chapter 3 is 
presented here in the results section.  The timeframe for this data collection was from 
February 4, 2016 to June 7, 2016.  I went to Ghana to collect the samples from all over 
the country based on what was described in Chapter 3.  There were no issues with 
quickly purchasing products from the outlets, as there was no reason for the outlets not to 
sell the drugs.  As mentioned in Chapter 3, stratified sampling was used to group and 
sample the population of the town or city based populations.  Simple random sampling 
method was used for sample collection. The goal of the study was to have a power of .08 




medium effect size 0.3 for LCS.  For each hypothesis, a 95% confidence with the alpha 
level (type 1 error) set to 0.05 (5%) was assumed.   
Out of the outlets and demographics, nearly all carried the medication except for 
government hospitals, which will not sell the mediation without prescription.  The total 
number of outlets in this study was 145.  Demographics of pharmacies and license 
chemical sellers are shown in Table 8; a majority of the drugs were purchased from LCS.  
Table 8.  
Descriptive Statistics of Location of Outlets  
Outlets Frequency Percent 
Big city pharmacies 23 28.0 
Whole sale pharmacies 6 7.3 
Small town pharmacies 17 20.7 
Big city LCS 19 23.2 
Small town LCS 46 20.7 
 
Analytical Results 
The mobile phase was made up of an aqueous solution composed of 0.05% 
Trifluoracetic Acid (TFA) and acetonitrile 40:60 (v/v), adjusted a pH to 3 and filtered 
through 0.45 µ membrane filter and sonicated before use.  Flow rate of mobile phase was 
maintained at 1.5 ml/min.  The column temperature maintained was ambient temperature.  
The detection was carried out at 210nm.  Injection volume 20 µl and total run time was 
3.5 min.  Column was Zorbax SB-CN HPLC column (150 × 4.6 mm, 3.5 μm, Agilent).  
Pyrimethamine was used as an internal standard.  An example of the chromatogram is 





Figure 5. Example of Chromatogram obtained for 50 ug/ml of artemether and 50 ug/ml 
of lumefantrine. 
A calibration curve was calculated and fitted by 1/x weighted regression of the peak-area 
ratios of peak height of drug to the peak height of the internal standard.  The standard 
used for the calibration were 0, 1, 5, 100, 500 and 1000 ug/ml.  The quality control 
samples were 1, 40, 80 and 800 ug/ml.  The concentration of the artemether and 
lumefantrine in the tablets were calculated using the linear curve and multiplied by 1000 
to represent the 1:1000 dilution for each tablet.  The final concentration was therefore in 
mg/ml.  The accuracy of the method was determined by using known concentrations of 
standard after it had been added to fixed concentration of the preanalyzed tablet solution. 




the known standards.  The recovery studies were performed in triplicate using standard 
addition method based on 10%, 100%, 1000% level and after which the recovery was 
calculated.  Based on this, average recovery was 99.2% for artemether and 99.4 
lumefantrine, which confirms accuracy of the assay.  Since some of the tablets had 
different amounts, all of them were standardized to 20mg/ml for artemether and 120 
mg/ml for lumefantrine.  Summary of the descriptive statistics of the samples is shown in 
Table 9.  On average the mean (SD) was 15.8 (5.5) and 102.5 (5.5) for all locations 
except for wholesale stores that did not have counterfeit drugs.  
Table 9  
Descriptive Statistics of Drug Concentrations  
  N mean sd min max 
Concentration of artemether (mg/ml)       
Private pharmacies in cities 16 16.2 5.7 0 20 
Wholesale stores 6 16.1 5.6 4.75 19 
Private pharmacies in small towns 
and villages 
17 15.5 0.5 14.8 19 
LCS in cities 46 15.6 5.3 1 19.8 
LCS in small towns and villages 65 15.6 5.1 0 20.8 
      
Concentration of lumefantrine (mg/ml)       
Private pharmacies in cities 16 104.8 34.6 0 120 
Wholesale stores 6 117.3 1.8 115 120 
Private pharmacies in small towns 
and villages 
17 96.3 34.6 26 118.5 
LCS in cities 46 100.1 29.8 17.5 119 
LCS in small towns and villages 65 100.6 29.5 15.75 119.3 
  
When the drugs were purchased the prices were also recorded to see if this could affect 




mean (sd) was 8.0 (3.8) Ghana Cedis.  (1 dollar on the average at the time of purchase 
was equivalent to 3.7 Ghana Cedis).  The summary is shown on Table 10.  
Table 10  
Summary of Cost for Purchasing the Drugs  
Location Mean N Std. Deviation 
Big city pharmacies 9.44 16 5.5 
Wholesale pharmacies 5.83 6 1.6 
Small town pharmacies 9.00 17 5.7 
Big city LCS 7.72 46 2.9 
Small town LCS 7.78 65 3.3 
Total 8.00 150 3.8 
 
 I next determined the definition of counterfeit drugs based on the concentration.  
The nominal value for artemether and lumefantrine were 20mg/ml and 120mg/ml 
respectively.  Generally, FDA considers these drugs as counterfeit (substandard) if the 
concentration is less than 20 % of the expected values.  In this case, all concentrations 
less than 16 ng/ml and 96 ng/ml of artemether and lumefantrine respectively were 
considered.  Table 11 shows a summary of counterfeit drugs based on the locations. 
Table 11  
Summary of Quality of all Drugs based on Location 
 Counterfeit Non- counterfeit 
Location Number % Number % 
Big city pharmacies 1 6.3 15 93.8 
Whole sale pharmacies 0 0.0 6 100.0 
Small town pharmacies 3 17.6 14 82.4 
Big city LCS 11 23.9 35 76.1 
Small town LCS 15 23.1 50 76.9 





Table 12.  
Summary of Quality of artemether and lumefantrine on Outlet  
 Counterfeit Non- counterfeit 











LCS 26 23.4 85 76.6 
 
Table 13.  
Summary of Quality of artemether and lumefantrine based on Presence or Absence of 
Scratch 
 Counterfeit Non- counterfeit 
Outlet number % number % 
No-Scratch 30 34.5 57 65.5 
Scratch 0 0 63 100 
 
Table 14.  
Summary of quality of artemether and lumefantrine only based on import or local 
manufacture 
 Counterfeit Non- counterfeit 
Outlet number % number % 
Local 0 0 23 100 
Imported 30 23.6 97 76.4 
 
Out of 150 drugs that were purchased, 30 (20%) of them were counterfeit.  Small 
town LCS had the highest percentage of counterfeit medication, while wholesale 




exactly the same.  Any tablet that had counterfeit lumefantrine also had counterfeit 
artemether.  Comparing pharmacies and LCS, LCS had more counterfeit drugs (about 
14% more) than pharmacies (Tables 12).  None of the locally manufactured medications 
were counterfeit (Tables 14).  All the counterfeit medications were imported drugs and 
had no mPedigree scratch-off panels on them (Tables 13). 
Analysis of Research Questions 
A few steps were taken in the analysis of research: several initial democratic 
variables were lumped (collapsed) to generate other relevant variables, nonparametric 
Pearson’s Chi square (χ2) tests were the primary analysis used to test the hypotheses, and 
other tests used linear regression to determine the correlation between the cost of 
medication and the quality of medication. 
RQ1 - Is there a difference between the percentage of counterfeit medication in 
pharmacies found in the cities and those found in the rural areas? 
Ho1: There is no significant difference between the percentages of counterfeit 
medication in pharmacies found in the cities versus those found in the rural areas. 
Ha1: There is a significant difference between the percentages of counterfeit 





Based on the results below, the p value (0.512) is > 0.05, (Table 15) the null hypothesis 
cannot be rejected. There is no significant difference (χ2 = 0.430, p = 0.512) between the 
quantity of counterfeit medication in pharmacies found in the cities versus those found in 
the rural areas. 
 
Table 15 
Comparing the Quality of Drugs in Cities versus Rural Areas  






Pearson Chi-Square .430 1 .512   
Continuity Correctionb .203 1 .652   
Likelihood Ratio .433 1 .510   
Fisher’s Exact Test    .545 .327 
Linear-by-Linear 
Association 
.428 1 .513   
N of Valid Cases 150     
 
RQ2 - Is there a difference in the percentage of counterfeit drugs between 
pharmacies and Licensed Chemical Sellers? 
Ho2: There is no significant difference in the percentage of counterfeit drugs 
between pharmacies and Licensed Chemical Sellers. 
Ha2: There is a significant difference in the percentage of counterfeit drugs 




Based on the results below, the p value (0.077) is > 0.05, (Table 17) the null 
hypothesis was not rejected. There is a no significant difference (χ2 = 3.127, p = 0.077) 
between the quantity of counterfeit drugs from pharmacy versus LCS.  
 
Table 16  
Comparing the Quality of Drugs in Pharmacy Versus LCS  






Pearson Chi-Square 3.127 1 .077   
Continuity Correctionb 2.358 1 .125   
Likelihood Ratio 3.484 1 .062   
Fisher's Exact Test    .103 .057 
Linear-by-Linear 
Association 
3.106 1 .078   
N of Valid Cases 150     
 
RQ3 - Is there a significant difference in the percentage of counterfeit drugs 
between those drugs imported and drugs locally manufactured? 
Ho3: There is no significant difference in the percentage of counterfeit drugs 
between those drugs imported versus drugs locally manufactured. 
Ha3: There is a difference in the percentage of counterfeit drugs between those 
drugs imported versus drugs locally manufactured. 
Based on the results below, the p value (0.009) is < 0.05, (Table 17) the null 
hypothesis was rejected in lieu of the alternative hypothesis. There is a significant 
difference (χ2 = 6.791, p = 0.009) between the quantity of counterfeit drugs from locally 





Comparing the Quality of Drugs in Locally Made Versus Imported 






Pearson Chi-Square 6.791 1 .009   
Continuity Correctionb 5.395 1 .020   
Likelihood Ratio 11.263 1 .001   
Fisher's Exact Test    .008 .004 
Linear-by-Linear 
Association 
6.746 1 .009   
N of Valid Cases 150     
 
RQ4 – Is there a correlation between the MPedigree scratch-off panel on the 
packaging and percent of counterfeit drugs? 
Ho4: There is no significant difference between the MPedigree scratch-off panel 
on the packaging and percent of counterfeit drugs. 
Ha4: There is a significant difference between the MPedigree scratch-off panel on 
the packaging and percent of counterfeit drugs. 
Based the results below, the p value (0.000) is < 0.05, (Table 18) the null hypothesis was 
rejected in lieu of the alternative hypothesis. There is a significant difference (χ2 = 
27.155, p = 0.000) between the quantity of counterfeit drugs from mPedigree scratch-off 
panel boxes versus those that were not scratched. 
Table 18 













Pearson Chi-Square 27.155 1 .000   
Continuity Correctionb 25.043 1 .000   
Likelihood Ratio 38.032 1 .000   
Fisher’s Exact Test    .000 .000 
Linear-by-Linear 
Association 
26.974 1 .000   
N of Valid Cases 150     
 
Using multiple regression analysis, it was found that the kind of store (Beta = .027, p = 
.714) and the location in a city or small town/village (Beta = -.021, p = .143) are not 
predictors of the quality artemether. Checking the same for lumefantrine the kind of store 
(Beta = -.008, p = .898) and the location (Beta = -.027, p = .682) were also not predictors 
of the quality of drugs.  For both artemether (Beta = -.521, p < .05) and lumefantrine (Beta 
= -.639, p < .05) the origin of the drug (local or imported) predictors for drug quality. This 
was also true for the present of mPedigree scratch-off panel on boxes. For both artemether 
(Beta = -.110, p < .01) and lumefantrine (Beta = -.151, p < .023), having the scratch was a 
predictor of the quality if the drugs. Regression results are shown on Table 19 and Table 






Table 19.  
Multiple linear regression results from comparing dependent and all independent 





t Sig. 95.0% 
Confidence 








(Constant) 299.029 34.823  8.587 .000 230.204 367.855 










Location Pham &LCS -1.949 15.139 -.008 -.129 .898 -31.870 27.972 
Location City&Small 
Town/Village 
-5.522 13.468 -.027 -.410 .682 -32.141 21.098 
Scratch 31.312 13.625 .151 2.298 .023 4.384 58.241 
















Table 20.  
Multiple linear regression results from comparing dependent and all independent 






    t Sig. 95.0% 
Confidence 









43.639 6.825  6.394 .000 30.149 57.129 
imported or Local drug 
-26.192 3.661 -.521 -
7.155 
.000 -33.427 -18.957 
LocationPham&LCS 
.806 2.967 .020 .272 .786 -5.058 6.671 
LocationCity&SmallTownVillage 
-.493 2.640 -.014 -.187 .852 -5.710 4.725 
Scratch 
4.020 2.670 .110 1.505 .134 -1.258 9.298 
a. Dependent Variable: Artemether_Mean  
 
The cost of each of these drugs were recorded. A correlation analysis was performed to 
check if there was c relation between the cost of drug and the quality of the drug. Cost of 
drug and the quality or he drug were correlated for both (Kedell’s: artemether r= .243, p 
<0.05 and Spearman’s: artemether r= .298, p <0.05) and lumefantrine (Kedell’s: 
artemether r= .190, p <0.05 and Spearman’s: r= .258 p <0. Results for correlation 







Table 21.  









Sig. (2-tailed) . .000 






Sig. (2-tailed) .000 . 






Sig. (2-tailed) . .000 






Sig. (2-tailed) .000 . 
N 150 150 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 22.  










Sig. (2-tailed) . .002 






Sig. (2-tailed) .002 . 









Sig. (2-tailed) . .001 






Sig. (2-tailed) .001 . 
N 150 150 
**. Correlation is significant at the 0.01 level (2-tailed). 
Conclusions 
Pearson Chi-Square analyses were conducted to examine relationships among 
variables.  These tests were conducted to investigate the quality of antimalarial 
medication.  Overall, results revealed that about 20% of the antimalarial medications 
tested were counterfeit. Even though the percent of counterfeit medication in LCS was 
higher than pharmacies, this was not statistically significant. The same applies to 
differences between cities and small towns/villages, this was not statistically significant.  
Statistically significant differences were found between imported and locally made 
drugs. The results form comparing drugs with mPedigree scratch-off panel boxes versus 
drugs those without were similar. Cost of the drug was also correlated with the quality of 
the drug. The implications of these findings as well as suggestions will be discussed in 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The main goal of this quantitative study was to explore the extent of antimalarial 
counterfeit medication by looking at the quantities of ATMT and LMFT sold in retail 
outlets in Ghana that is counterfeit.  Fake and substandard drugs need to be addressed due 
to the threats to patients: failure to provide effective treatments, adulteration with toxic 
chemicals, and substandard drugs that can lead the parasites to become resistant to the 
medications (Attaran et al., 2012).  The amount of ATMT and LMFT purchased from 
retail outlets in Ghana was determined using validated analytical methods and compared 
to the expected amounts.  Overall, results revealed about 20% of drugs purchased were 
counterfeit.  The findings and conclusions of this study are discussed in the following 
section.  
Interpretation of the Findings 
Difference between Locations  
The first set of findings about counterfeit medication relates to the following 
question: Is there a difference between the percentage of counterfeit medication in drug 
stores found in cities and those found in the rural areas?  Results revealed no statistical 
difference between cities and rural areas (see Table 18).  Despite this study’s results, 
according to Gasmelseid (2016), not only is there a huge variation between geographic 
regions when it comes to the prevalence of counterfeit medications, variations can also 




likely because these medications in the rural areas are purchased from the cities, and they 
may have the same sources. 
Difference between Pharmacies and LCS  
The next set of findings about counterfeit medication relates to the following 
question: Is there a difference in the percentage of counterfeit drugs between pharmacies 
and licensed chemical sellers?  Results show some difference between pharmacies and 
LCS, with pharmacies exhibiting higher quality, but this difference was not statistically 
significant (Table 19).  Because of the structure of pharmacies compared to LCS, it was 
expected to have a significantly higher.  LCS are usually independently owned by 
nonpharmacists, usually by pharmacy technicians at best, and no training is required to 
obtain a license (FHI360, 2013).  This means LCS are prone to illegal practices such as 
sale of prescription medication, which is illegal but overlooked by authorities in Ghana. 
The fact that there is no significant difference also shows that they likely purchase from 
similar sources.  
Difference between Imported and Locally Manufactured Drugs 
The next finding relates to the following question: Is there a significant difference 
in the percentage of counterfeit drugs between those drugs imported and drugs locally 
manufactured?  Results revealed that there is a statistical difference between the qualities 
of drugs that were manufactured locally compared to import ones (Table 20).  Ghana has 
a well-established and developing pharmaceutical manufacturing base, and this report 
provides profiles of six of the major Ghana pharmaceutical manufacturers.  The profiles 




many common constraints for local pharmaceutical manufacturing development in 
Ghana.  Locally manufactured drugs make about 30% of drugs in the Ghanaian 
pharmaceutical market.  A majority (70%) of medication used in Ghana is mostly 
imported and they are mostly Southeastern Asia (India and China).  There is generally the 
presumption that I imported goods including medication have higher quality that locally 
manufactured goods.  The locally manufactured medication also tends to be higher in 
prices.  Unfortunately, most of the 750 million counterfeit drugs seized in Africa by 
World Customs Organization (WCO) since 2012 were from India and China (Barbiere, 
2017).  It is also important to mention that cost of the drug was also found correlated with 
the quality of the drug. 
Effect of mPedigree Scratch-off Panel 
The final finding relates to the following question: Is there a correlation between 
the mPedigree scratch-off panel on the packaging and percent of counterfeit drugs? 
Results revealed that there is a statistical difference between the qualities of drugs with 
the mPedigree scratch-off panel compared to those without (Table 21).  This was the 
largest decider of the quality of drug as all counterfeit medication found in this study had 
no mPedigree scratch-off panel.  This was expected because drugs with this mPedigree 
scratch-off panel are supposed to be good quality and from the manufacturer.  
Findings in Relation to Theoretical Framework 
The use of explanatory theory in the study is supported by the results of the study 
that 20% of drugs are counterfeit, which empirically defined the scope of the problem. 




the quality of the drugs.  The concentration of the drugs correlated with the amount of 
drug that will occupy the receptors which correlated with response/efficacy.  The total 
efficacy can only be achieved if all the receptors needed to destroy the plasmodium 
parasite are occupied.  In this case 20% of the drugs will not achieve total efficacy.  It 
also means that there will be no difference in efficacy if we compared location (cities and 
rural) and LCS versus pharmacies.  On the other hand, there will be differences in 
efficacy between imported versus locally manufactured and the presence versus absence 
of the mPedigree scratch-off panel.  
Limitations of the Study 
Limitations for this study include generalization and whether the results are valid 
and reliable.  Examining two antimalarial medications in Ghana may not provide a 
complete representation of all antimalarial medication in Africa.  One way to overcome 
this in future research is to study other medications and include other countries in the sub 
region.  Another limitation of this study is that the study may not capture all possible 
outlets.  The data was based on data for a country that lacks good data collection systems.  
The presence of possible illegal outlets is also a limitation, because these are not being 
counted.  Some of these were solved by making sure the data collection process is done 
based on statistics, using random sampling and other research methods. 
Recommendations  
A recommendation for future researchers is to include different countries and 
different experimental designs as a part of their studies.  A recommendation to healthcare 




mediation in the system and eliminate it.  From this study, all drugs with the mPedigree 
scratch-off panel were of good quality, leading to a recommendation to promote only 
drugs with a mPedigree scratch-off panel.  Another recommendation is to promote locally 
manufactured medication; all drugs imported from India and China should be scrutinized 
to make sure they are not counterfeit.  The government will need to hold companies who 
are selling and marketing counterfeit medication accountable to deter others.  
Implications  
The results from this research can help the Ghana standard boards, the Ghana 
health service, other stakeholders, and policymakers understand the scope of counterfeit 
antimalarial medication in Ghana.  Government/nongovernment organizations and the 
society at large will benefit from this information.  With a better understanding of how 
much antimalarial medication is counterfeit in Ghana, organizations can create 
interventions to minimize the effects of counterfeit antimalarial medication in Ghana.  
Some of the findings may also have a positive impact on public health.  The results show 
that there is no difference between the quality of the medication between cities and rural 
areas of the country, which implies they likely have similar sources.  The results also 
inform the public on the quality of medication based on mPedigree scratch-off panels; 
none of the drugs in this study with mPedigree scratch-off panel were counterfeit, which 
indicates the public should purchase only drugs with mPedigree scratch-off panel and 
locally manufactured instead of imported medication.  With these results, there can be 
advocacy to get the government to provide subsidies to local companies to help drive the 




buying imported drugs.  Finally, the names of the companies with the fake/counterfeit 
drugs will be given to the authorities for further investigation, so the sources of these 
counterfeit drugs can be cut off.  
Conclusions 
The outcomes, the results, and the lessons learned from the results of this study 
have many implications that can lead to positive social change (e.g., awareness of ways 
to acquire quality medication, understanding of the distribution of counterfeit medication 
and possible reduction, or eradication of the sources of these counterfeit medications) not 
only in Ghana but also in other sub-Saharan African countries.  The results from this 
study can be used by all stakeholders to effectively control the amount of counterfeit 
medication in the Ghana which is a public health issue.  For example, the findings of this 
study suggest drugs with mPedigree scratch-off panel are likely to be of high quality, so 
stakeholders should work together to create awareness and to educate people about how 
this works and why it is important to purchase only drugs with these panels.  Results also 
reveal that all counterfeit drugs were imported.  Therefore, stakeholders should also work 
together to make locally manufactured drugs more assessable and encourage/educate the 
public to use locally manufactured drugs.  
Malaria is still an epidemic in many parts of the world and it still affects millions 
of people worldwide.  Malaria can be treated with several drugs and these drugs work 
well if used appropriately and contain the right amounts of the active ingredient.  In this 
study, 20% of these drugs were found to be counterfeit.  This study begins to help us 




counterfeit medication.  Knowing the distribution will help with the initiation of 
programs to help address this problem.  
In summary, in the attempt to eradicate of malaria, secondary prevention plays a 
pivotal role, which means that people infected by the parasite need to be treated quickly 
and efficaciously to curb the spread of the disease.  All medications therefore need to 
have the correct active ingredients, the correct regimens adhered to, and the correct use 
for the right disease.  Tackling the issue of counterfeit medication and making quality 
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